Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • GABAB PAM for cough
  • M4 PAM for schizophrenia & other psychosis
  • ADX71149 for epilepsy
  • GABAB PAM for substance use disorder
  • Dipraglurant for post-stroke sensorimotor recovery
  • mGlu7 NAM for stress related disorders including PTSD
  • mGlu2 NAM for mild neurocognitive disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 02.21
    2012

    Addex Pharmaceuticals 2011 Financial Results this Thursday

  • 02.10
    2012

    Addex to present at the BIO CEO & Investor Conference

  • 11.28
    2011

    Addex Scientists Discover Glucagon-like-peptide-1 (GLP-1) Induced Interaction Between GLP-1 and Gastric Inhibitory Peptide (GIP) Receptors the addex allosteric modulator platform enabled breakthrough discovery, advancing the understanding of glp-1 mediated gpcr signaling

  • 11.02
    2011

    Addex Presents Data on Allosteric Modulators of GPCRs at the Discovery on Target Conference

  • 10.24
    2011

    Addex to Present at the BIO Investor Forum in San Francisco

  • 10.19
    2011

    Addex to Present in NYC at the Newsmakers in the Biotech Industry conference hosted by BioCentury and Thomson Reuters

  • 10.03
    2011

    Addex to Present Progress on Multiple Allosteric Modulator Programs for Neurodegenerative and other Neurological Disorders

  • 09.26
    2011

    Addex to Present at the Jefferies 2011 Global Healthcare Conference in London

  • 09.02
    2011

    Addex Regains Rights to Parkinson’s Drug Candidates from Merck

  • 08.15
    2011

    Addex Pharmaceuticals Appoints Dr Bharatt Chowrira as CEO

    Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next

Contact us

If you have any questions please let me know
  • Contact form
2026 © Addex therapeutics